Table 3. Major results from the HER2-scores analyses (n=47).

HER2-scores characteristics	Fraction	Percentage
Primary tumours with 3+	23/47	49
Primary tumours with 2+ or 3+	26/47	55
Lymph node metastases with 3+	22/47	47
Lymph node metastases with 2+ or 3+	26/47	55
Unchanged HER2-scores in lymph node metastases vs the primary tumour	40/47	85
Changed HER2-scores in lymph node metastases vs the primary tumour	7/47	15
Patients who had 0 or 1+ in primary tumours and changed to 2+ or 3+ in lymph node metastases	0/47	0
Patients who had 2+ or 3+ in primary tumours and changed to 0 or 1+ in lymph node metastases	0/47	0